certain levels of HDR competency, though not necessarily genome stability. Most spontaneous DSBs are thought to be caused by perturbations during DNA replication 2 . In wild-type cells, protecting stalled DNA replication forks from nuclease-mediated degradation may prevent the formation of DSBs under physiological conditions 22, 23 . However, in a scenario in which forks cannot be adequately protected, such as in cells doubly deficient in BRCA1 and 53BP1 22 , replication-associated DSBs would ensue, and some of these breaks might be aberrantly repaired by SSA (Fig. 2) . The finding that Rad52 deletion partially suppresses the development of T-cell lymphoma in ATMdeficient mice supports the oncogenic potential of SSA 24 . Although mice doubly deficient in BRCA1 and 53BP1 do not appear to develop spontaneous tumors 10 , it would nevertheless be interesting to test whether they are tumor prone when challenged with carcinogens or agents that induce replication stress. Finally, because BRCA1-deficient tumor cells can become resistant to chemotherapeutic agents through loss of 53BP1, Rad52 inhibitors may prove to be useful in a clinical setting. In any case, the work by Ochs et al. 5 underscores that HDR is complex and consists of both error-free and error-prone subpathways whose activities must be tightly regulated and fine-tuned to ensure genome integrity. Future studies aimed at enhancing understanding of the causes of synthetic viability and chemotherapy resistance may enable rational design of new treatment regimens and more effective cancer therapies.
At first, it may seem counterintuitive that 53BP1 blocks DSBs from nucleases yet at the same time is required for limited end resection. Recent studies have shown that although 53BP1 initially accumulates at DSB sites, it is subsequently deposited at regions more distal to the break in a manner requiring the ubiquitin ligase activity of BRCA1 (refs. 18-20) . It is possible that BRCA1-mediated repositioning of 53BP1 away from DSB termini to the periphery effectively delineates an insulated chromatin domain within which end resection and error-free HDR is permitted. When BRCA1 is absent, a substantial amount of 53BP1 may remain near the break site, blocking nuclease access and thereby suppressing end resection and HDR. When both BRCA1 and 53BP1 are absent, those DNA ends that exhibit limited resection in BRCA1-deficient cells are capable of supporting Rad51-dependent GC because they are no longer blocked by 53BP1.
Depletion of 53BP1 leads not only to increased levels of GC but also to increased SSA in BRCA1-deficient cells 5, 21 (Fig. 2) . Indeed, gene targeting efficiency, a functional indicator of successful GC, is impaired in BRCA1-deficient cells and is only partially restored after loss of 53BP1 (ref. 11). Moreover, in agreement with their increased reliance on SSA-mediated mutagenic HDR, cells doubly deficient in BRCA1 and 53BP1, compared with their wildtype counterparts, display increased genomic instability 10, 12 and are hypersensitive to Rad52 inhibition 5 . Together, these data strengthen the emerging view that organismal viability requires A route to new cancer therapies: the FA pathway is essential in BRCA1-or BRCA2-deficient cells
Christophe Lachaud & John Rouse
Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers. In BRCA1-or BRCA2-mutated cells, loss of FANCD2, a key FA-pathway component, causes levels of replication stress to soar out of control, thereby triggering replication-fork catastrophe and cell death (Fig. 1) . FANCD2 is ubiquitinated in response to replication stress by an E3 ubiquitin ligase comprising a group of eight FA 'core complex' proteins 5 . FANCD2 ubiquitination is known to be required to allow cells to tolerate perturbations during DNA replication 6, 7 and n e w s a n d v i e w s The observation that mutations in FANCD2, BRCA1 or BRCA2 can cause FA suggests that these gene products may perform equivalent functions. However, recent studies by Michl et al. 2 and Kais et al. 3 reveal that such functional equivalence is not always the case, because FANCD2 acquires a vital role in cells with BRCA1 or BRCA2 mutations 2 . Precisely how FANCD2, and its ubiquitination by the FA core complex, prevents replication stress from rising to deadly levels in BRCA-mutated cells is not entirely clear, but Michl et al. 2 provide important clues. They show that FANCD2 limits damage to replication forks, possibly by helping to arrest and subsequently restart forks that stall and/or collapse in BRCA-mutated cells (Fig. 1) . Further work is needed to understand how FANCD2 enables these protective responses.
Kais et al. 3 provide additional clues by presenting evidence that the synthetic lethality resulting from loss of FANCD2 ubiquitination in cells with mutations in BRCA1 or BRCA2 may reflect an unanticipated role of FANCD2 in promoting a mode of DNA repair termed alternative end-joining (alt-EJ) 3 . In support of this view, it has previously been shown that loss of a specialized DNA polymerase, polymerase θ (POLθ), which promotes alt-EJ, is synthetic lethal in cells with BRCA1 or BRCA2 mutations 13, 14 . The implication from these data is that collapsed forks, which cannot be repaired because HR is not functional in cells with BRCA1 or BRCA2 defects, can be rescued by alt-EJ. Kais et al. 3 now show that POLθ is recruited to stalled forks in a manner dependent on FANCD2 ubiquitination, and FANCD2-depleted cells show a decreased capacity for alt-EJ. These data are consistent with an essential role of alt-EJ, facilitated by ubiquitin-FANCD2, in cells with BRCA1 or BRCA2 mutations. Interestingly, two other proteins in addition to POLθ are known to be recruited to stalled forks by ubiquitin-FANCD2 and may therefore also contribute to protecting BRCA-defective cells. These are the HR-promoting factor CTIP 15 and the FAN1 nuclease (refs. 16,17) , which works closely with ubiquitin-FANCD2 in stabilizing stalled replication forks. CTIP loss does not kill BRCAmutated cells 3 , but the effect of FAN1 loss has yet to be examined and will be an important area of future investigation.
Synthetic lethality provides a conceptual framework for the development of drugs that are selectively toxic in specific genetic backgrounds associated with human disease. A classic example is the toxicity of poly-ADP ribose polymerase (PARP) inhibitors in cells with BRCA1 or BRCA2 mutations. PARP is involved in repairing single-strand breaks, and is thus also essential for survival of BRCA1-or BRCA2-mutated cells 3 .
Both BRCA1 and BRCA2 are important for DNA repair via homologous recombination (HR), which repairs and resets stressed and broken DNA replication forks 4 . BRCA1 has multiple roles in HR, whereas BRCA2 acts primarily as a reservoir of the RAD51 recombinase and helps to deposit RAD51 onto DNA breaks, thereby facilitating HR 8 . Intriguingly, deposition of RAD51 by BRCA2 has a forkprotective role that prevents replication stress in a manner separate from HR 9 . The biological importance of these various forkprotective functions is underscored by the high degree of replication stress observed in cells with BRCA1 and BRCA2 mutations; the resulting genetic instability is likely to explains why cancer arises when BRCA1 or BRCA2 function is impaired.
Like mutations in FANCD2, some BRCA1 and BRCA2 mutations can cause FA, which is characterized by bone-marrow failure, developmental defects and predisposition to a range of cancers 10, 11 . The FA pathway is responsible for facilitating repair of DNA interstrand crosslinks, which block replisome progression 5 , and it is also essential for protecting replication forks under replication-stress conditions 12 .
PARP inhibition causes the accumulation of single-strand breaks, which, if they persist into S phase, can cause fork collapse. Because the repair of collapsed forks requires HR, PARP inhibitors cannot be tolerated in BRCA-mutated cells 18 . PARP inhibitors have shown promise in clinical trials, but intrinsic and acquired resistance is a major limitation in their use in cancer treatment, and thus there is a pressing need for alternatives 19 . The two new studies suggest that inhibiting FANCD2 function may represent a promising strategy for the treatment of BRCAdeficient cancers (Fig. 2) . This possibility is strongly supported by the exciting observation that FANCD2 depletion impairs the growth of tumors derived from breast cancer cells xenotransplanted into mice 3 .
From a clinical perspective, how might FANCD2 function be inhibited in BRCA1-or BRCA2-mutated cancers? FANCD2 is not an enzyme and therefore may not be susceptible to drug inhibition; however, preventing its ubiquitination by inhibiting the E3 ligase activity of the FA core complex may provide a means to selectively kill BRCAmutated tumors. Alternatively, interfering with enzymes that act downstream of ubiquitin-FANCD2 may be an option. An obvious candidate is POLθ, which is recruited to stressed forks by ubiquitin-FANCD2 (ref. Figure 2 Strategy to selectively target BRCA1-or BRCA2-deficient cancers by inhibiting FANCD2 function. In response to replication stress, FANCD2 is ubiquitinated by the FA core complex, an E3 ligase, and this modification is essential for FANCD2-mediated replication-fork protection. Inhibitors of FA core-complex activity, which would prevent FANCD2 ubiquitination, should therefore be toxic in BRCA1-or BRCA2-mutated cancers. Alternatively, inhibiting enzymes that function downstream of ubiquitin-FANCD2, such as POLθ or FAN1 nuclease, may be selectively lethal in these cancers. It has been shown that BRCA-mutated cells cannot tolerate loss of POLθ (refs. 13,14) but it is not yet known whether FAN1 function is also essential in BRCAdeficient cells. 13, 14 ( Fig. 2) . FAN1 is also recruited to stalled forks by ubiquitin-FANCD2 (ref. 17) , and if, like FANCD2, it proves to also be required to counteract elevated fork-stress levels in BRCA-mutated cells, small-molecule FAN1 inhibitors may also be selectively toxic in BRCA-mutated tumors (Fig. 2) . These considerations provide new hope for the development of new treatments for breast and ovarian cancers caused by BRCA1 and BRCA2 mutations. It is worth considering that heightened replication stress is not unique to cancers caused by BRCA mutations. Indeed, activating a variety of oncogenes causes replication stress 20, 21 , and thus pathways that limit Initiation is the rate-limiting step in translation of eukaryotic mRNAs. For most mRNAs, initiation begins with the assembly of the preinitiation complex at the mRNA 5′ cap. This complex includes several initiation factors and the small ribosomal subunit. Initiation ends when the large ribosomal subunit joins the preinitiation complex 'docked' at a codon that is recognized as the translation start (usually AUG). The ribosome is then set to begin elongation of the peptide chain. With some important exceptions, the first and last steps of initiation occur in a similar manner on most eukaryotic mRNAs. It is the ribosome's journey from the 5′ cap to a translation start that varies among different mRNAs. Highly regulated mRNAs are known to contain long and structured 5′ leaders upstream of the protein-coding region. Therefore, the specificity of the translation regulation of individual mRNAs is often determined by what happens to ribosomes before they reach the protein-coding sequence. Despite enormous interest in this process, it remains poorly characterized. A long time ago, it was conjectured that preinitiation complexes reach the translation start codon by progressive scanning of the mRNA from the 5′ end toward the 3′ end 1 . Overwhelming experimental observations obtained during the past three decades support the scanning model of translation initiation, yet ribosome scanning of mRNAs has never been demonstrated directly in vivo. Unlike elongating ribosomes, preinitiation complexes are unstable and therefore difficult to isolate. Now, in Nature, Preiss and colleagues 2 describe a new method, TCP-seq, that detects traces of scanning ribosomes on mRNAs, thus offering a unique and powerful tool for studying translation initiation genome wide.
TCP-seq is based on the ribosome profiling technique developed in 2009 (ref. 3) , which provides information on the locations of elongating ribosomes on RNAs. During ribosome profiling, ribosomes are arrested on RNAs, usually through treatment with inhibitors of translation elongation. Subsequent addition of RNase digests RNA that is not protected by an arrested ribosome. The protected RNA fragments, or n e w s a n d v i e w s npg
